Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03049852 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium
A Phase 2 study, sponsored by Cloudbreak Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT03049852 is a Phase 2 study that has completed, run by Cloudbreak Therapeutics. The registered enrollment target is 75 participants.
The verdict
NCT03049852, a Phase 2 study, has completed, sponsored by Cloudbreak Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
Interventions
- DRUG Vehicle
- DRUG CBT-001 single dose
- DRUG CBT-001 Multi-dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2017-04-15 |
| Est. Completion | 2018-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03049852
The ClinicalTrials.gov registry entry for NCT03049852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cloudbreak Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT03049852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03049852 about?
NCT03049852 is a clinical study titled "Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium". Stage 1: Single Ascending Dose, Safety, Tolerability and Pharmacokinetics (n=24) Stage 2: Multiple Dose, Safety and Efficacy Study with 28-day Dosing and 5 months Followup (n=51)
What is the current status of trial NCT03049852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2017-04-15. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT03049852?
The interventions under investigation include: Vehicle (DRUG), CBT-001 single dose (DRUG), CBT-001 Multi-dose (DRUG).
Who is sponsoring clinical trial NCT03049852?
This trial is sponsored by Cloudbreak Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.